Kazia Therapeutics – overview and update with CEO James Garner

Published on 19 May 2021

Kazia Therapeutics (KZA) is an oncology-focused drug development company. Its drug candidates are designed to treat diseases which are poorly served by existing therapies. In this video, James Garner, CEO, highlights the company’s business model, newest drug asset and progress over the next year.

Share this with friends and colleagues